Chemo or Chemo-Free Regimens in Heavily Pretreated Multiple Myeloma? Role of Bendamustine-BortezomibDexamethasone (BVD) in Novel Agents' Era

被引：0
|
作者：
Nappi, Davide [1 ]
Catalano, Lucio [2 ]
Pareto, Anna Emanuele [2 ]
Musuraca, Gerardo [3 ]
Ronconi, Sonia [3 ]
Ceccolini, Michela [3 ]
Cangini, Delia [3 ]
Pane, Fabrizio [2 ]
Martinelli, Giovanni [3 ]
机构：
[1] Dept Hematol & CBMT, Bolzano, Italy
[2] AOU Federico II, Naples, Italy
[3] Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Hematol Unit, Meldola, FC, Italy
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2022年 / 22卷
关键词：
MM; multiple myeloma; bendamustine; pegfilgrastim; relapsed; refractory;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MM-494
引用
收藏
页码：S426 / S426
页数：1
相关论文
共 26 条
  • [21] Early upfront plerixafor administration on day 3 in the "chemo-free" mobilization regimen G-CSF plus Plerixafor, for Multiple Myeloma patients: a retrospective single center experience
    Bozzoli, Valentina
    Mazzotta, Paola
    Matera, Rosella
    Messa, Anna Rita
    Dargenio, Michelina
    Canaris, Donato
    Di Renzo, Nicola
    BONE MARROW TRANSPLANTATION, 2018, 53 : 769 - 769
  • [22] Impact of daratumumab/bortezomib/thalidomide and dexamethasone induction therapy on chemo-free stem cell mobilization in transplant-eligible newly diagnosed multiple myeloma: a multicenter real-world experience
    Porrazzo, Marika
    Moscato, Tiziana
    Sapienza, Giuseppe
    Accardi, Fabrizio
    Patti, Caterina
    Cangialosi, Clotilde
    Costanza, Carmelo
    Bono, Roberto
    Tringali, Stefania
    Rotolo, Cristina
    Gigliotta, Emilia
    Rizzuto, Andrea
    Ingrasci, Manuela Giuseppa
    Butera, Giulia
    Di Noto, Laura
    Santoro, Alessandra
    Marfia, Anna
    Botta, Cirino
    Siragusa, Sergio
    Martino, Massimo
    Castagna, Luca
    HAEMATOLOGICA, 2025, 110 (03) : 791 - 794
  • [23] A comparison of chemo-free strategy with G-CSF plus plerixafor on demand versus intermediate-dose cyclophosphamide and G-CSF as PBSC mobilization in newly diagnosed multiple myeloma patients: An Italian explorative cost Analysis
    Laszlo, D.
    Marcacci, GP.
    Martino, M.
    Radice, D.
    Rabascio, C.
    Lucchetti, B.
    Magaro, A.
    Caime, A.
    Menna, S.
    Lionetti, MT.
    Bertolini, F.
    TRANSFUSION AND APHERESIS SCIENCE, 2020, 59 (05)
  • [24] Overall Survival Patterns in Patients with Multiple Myeloma in the Era of Novel Agents and the Role of Initial Clinical Presentation and Comorbidities: A Population-Based Study
    Oortgiesen, Berdien
    van Roon, Eric N.
    Joosten, Peter
    Kibbelaar, Robby
    Storm, Huib
    Hovenga, Sjoerd
    Van Rees, Bas P.
    Woolthuis, Gerhard
    Veeger, Nic J. G. M.
    Hoogendoorn, Mels
    BLOOD, 2014, 124 (21)
  • [25] Role of serum free light chain assay in the detection of early relapse and prediction of prognosis after relapse in multiple myeloma patients treated upfront with novel agents
    Tacchetti, Paola
    Pezzi, Annalisa
    Zamagni, Elena
    Pantani, Lucia
    Rocchi, Serena
    Zannetti, Beatrice Anna
    Mancuso, Katia
    Rizzello, Ilaria
    Cavo, Michele
    HAEMATOLOGICA, 2017, 102 (03) : E104 - E107
  • [26] SERUM FREE LIGHT CHAIN EVALUATIONS IN MULTIPLE MYELOMA PATIENTS TREATED WITH NOVEL AGENTS: ROLE IN DETECTING EARLY RELAPSE AND DEFINIG THE PROGNOSIS ON AFTER-RELAPSE OUTCOMES
    Tacchetti, P.
    Casadei, C.
    Pezzi, A.
    Zamagni, E.
    Rocchi, S.
    Pantani, L.
    Zannetti, B. A.
    Mancuso, K.
    Rizzello, I.
    Marzocchi, G.
    Borsi, E.
    Terragna, C.
    Cavo, M.
    HAEMATOLOGICA, 2015, 100 : 101 - 101
123